Cramer thinks it is clear that Allergan is basing much of its independence on its pipeline, but he believes investors would take their money and run if this pipeline turns out to be not as good as Pyott has claimed.
Cramer suggests investors sell half of their position in Allergan and let the other half run. He thinks the stock would be closed to $120 or $125 if Valeant were not involved.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts